Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01

Authors

Kim N. Chi (ORCID: https://orcid.org/0000-0002-3782-7226)
Nianzeng Xing
Didier Meulendijks (ORCID: https://orcid.org/0000-0002-4580-426X)
Eva Hellmis (ORCID: https://orcid.org/0000-0002-7780-8759)
Julianne Lima (ORCID: https://orcid.org/0000-0003-3837-9717)
Arun Azad (ORCID: https://orcid.org/0000-0001-7350-5622)
Mehreteab Aregay
Mikio Sugimoto
Neeraj Agarwal
Yüksel Ürün
Andrew J. Armstrong

Institutions

University of British Columbia (CA)
Ankara University (TR)
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Kagawa University (JP)
University of Utah (US)
Peter MacCallum Cancer Centre (AU)
Peking Union Medical College Hospital (CN)
AstraZeneca (Brazil) (BR)
Duke Medical Center (US)
Center for Cancer Research (US)

Publication Details

Journal: Future Oncology
Published: 2026-04-14
DOI: https://doi.org/10.1080/14796694.2026.2655433
Primary Topic: Prostate Cancer Treatment and Research
Type: article
Field-Weighted Citation Impact: 0.00

Funders

AstraZeneca
American Society of Clinical Oncology

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01

Kim N. Chi, Nianzeng Xing, Didier Meulendijks, Eva Hellmis et al.

Apr 14, 2026

Future Oncology

Prostate Cancer Treatment and Research

article

Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01

Kim N. Chi, Nianzeng Xing, Didier Meulendijks, Eva Hellmis, Julianne Lima, Arun Azad, Mehreteab Aregay, Mikio Sugimoto, Neeraj Agarwal, Yüksel Ürün, Andrew J. Armstrong

April 14, 2026article en

Abstract

No abstract available for this paper.

Future OncologyVol. 22(10)

University of British Columbia (CA), Ankara University (TR), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Kagawa University (JP), University of Utah (US), Peter MacCallum Cancer Centre (AU), Peking Union Medical College Hospital (CN), AstraZeneca (Brazil) (BR), Duke Medical Center (US), Center for Cancer Research (US)

AstraZeneca, American Society of Clinical Oncology

Openalex Percentile: Top 23%

Prostate Cancer Treatment and Research

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01 — Kim N. Chi, Nianzeng Xing, et al. · Future Oncology (2026) | TGRS Research Map | TGRS